Efficacy and safety of calcipotriol (MC 903) ointment in psoriasis vulgaris: A randomized, double-blind, right/left comparative, vehicle-controlled study
- 31 December 1992
- journal article
- clinical trial
- Published by Elsevier in Journal of the American Academy of Dermatology
- Vol. 27 (6) , 983-988
- https://doi.org/10.1016/0190-9622(92)70299-u
Abstract
No abstract availableKeywords
This publication has 11 references indexed in Scilit:
- Comparative study of calcipotriol (MC 903) ointment and betamethasone 17-valerate ointment in patients with psoriasis vulgarisJournal of the American Academy of Dermatology, 1992
- Double-blind, right/left comparison of calcipotriol and betamethasone valerate in treatment of psoriasis vulgarisThe Lancet, 1991
- In vitro metabolism of Calcipotriol (MC 903), a vitamin D analogueBiochemical Pharmacology, 1990
- Treatment of Psoriasis by the Topical Application of the Novel Cholecalciferol Analogue Calcipotriol (MC 903)Archives of Dermatology, 1989
- A double-blind, placebo-controlled trial of topical 1,25-dihydroxycholecalciferol in psoriasisBritish Journal of Dermatology, 1989
- A double-blind study of topical 1α,25-dihydroxyvitamin D3 in psoriasisBritish Journal of Dermatology, 1989
- A novel approach for the evaluation and treatment of psoriasis: Oral or topical use of 1,25-dihydroxyvitamin D3 can be a safe and effective therapy for psoriasisJournal of the American Academy of Dermatology, 1988
- Effects of a novel vitamin D analogue MC 903 on cell proliferation and differentiation in vitro and on calcium metabolism in vivoBiochemical Pharmacology, 1988
- Successful treatment of psoriasis with topical application of active vitamin D3 analogue, 1α, 24-dihydroxycholecalciferolBritish Journal of Dermatology, 1986
- Severe Psoriasis – Oral Therapy with a New RetinoidDermatology, 1978